Published in Cell on July 22, 2010
The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci (2012) 4.92
Amyloid-β and tau--a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci (2010) 3.61
Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat Med (2012) 3.31
Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell (2012) 3.16
Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A (2011) 3.11
Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J Neurosci (2011) 2.96
Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci (2012) 2.92
The many faces of tau. Neuron (2011) 2.89
Resolving controversies on the path to Alzheimer's therapeutics. Nat Med (2011) 2.78
Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med (2012) 2.77
Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron (2010) 2.68
Functional links between Aβ toxicity, endocytic trafficking, and Alzheimer's disease risk factors in yeast. Science (2011) 2.66
Tau reduction prevents Abeta-induced defects in axonal transport. Science (2010) 2.57
Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb Perspect Med (2012) 2.39
Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat Neurosci (2015) 2.38
Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer's disease. Nat Neurosci (2013) 2.26
Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med (2012) 2.01
In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J Neurosci (2011) 2.00
Apolipoprotein E4 causes age- and Tau-dependent impairment of GABAergic interneurons, leading to learning and memory deficits in mice. J Neurosci (2010) 1.93
Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer aβ oligomer bound to cellular prion protein. Neuron (2013) 1.87
Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat Med (2014) 1.85
Soluble Aβ oligomer production and toxicity. J Neurochem (2011) 1.83
Life extension factor klotho enhances cognition. Cell Rep (2014) 1.81
Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc Natl Acad Sci U S A (2013) 1.73
Functional genomic screen and network analysis reveal novel modifiers of tauopathy dissociated from tau phosphorylation. Hum Mol Genet (2011) 1.72
Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. Cold Spring Harb Perspect Med (2011) 1.68
Brain amyloid-β oligomers in ageing and Alzheimer's disease. Brain (2013) 1.64
Three dimensions of the amyloid hypothesis: time, space and 'wingmen'. Nat Neurosci (2015) 1.60
The intersection of amyloid beta and tau at synapses in Alzheimer's disease. Neuron (2014) 1.59
MAPT expression and splicing is differentially regulated by brain region: relation to genotype and implication for tauopathies. Hum Mol Genet (2012) 1.58
Apolipoprotein E epsilon4 does not modulate amyloid-β-associated neurodegeneration in preclinical Alzheimer disease. AJNR Am J Neuroradiol (2012) 1.57
Synapses and Alzheimer's disease. Cold Spring Harb Perspect Biol (2012) 1.57
Tau loss attenuates neuronal network hyperexcitability in mouse and Drosophila genetic models of epilepsy. J Neurosci (2013) 1.54
Spreading of pathology in neurodegenerative diseases: a focus on human studies. Nat Rev Neurosci (2015) 1.53
Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. Trends Neurosci (2011) 1.51
The complex PrP(c)-Fyn couples human oligomeric Aβ with pathological tau changes in Alzheimer's disease. J Neurosci (2012) 1.50
Amyloid-β--associated clinical decline occurs only in the presence of elevated P-tau. Arch Neurol (2012) 1.48
Tau overexpression impacts a neuroinflammation gene expression network perturbed in Alzheimer's disease. PLoS One (2014) 1.46
Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLoS One (2011) 1.45
Intracellular amyloid β oligomers impair organelle transport and induce dendritic spine loss in primary neurons. Acta Neuropathol Commun (2015) 1.45
Molecular mechanisms of dendrite stability. Nat Rev Neurosci (2013) 1.44
Riluzole rescues glutamate alterations, cognitive deficits, and tau pathology associated with P301L tau expression. J Neurochem (2015) 1.44
Amyloid-β associated volume loss occurs only in the presence of phospho-tau. Ann Neurol (2011) 1.44
Fyn kinase regulates the association between amyloid precursor protein and Dab1 by promoting their localization to detergent-resistant membranes. J Neurochem (2011) 1.43
The CAMKK2-AMPK kinase pathway mediates the synaptotoxic effects of Aβ oligomers through Tau phosphorylation. Neuron (2013) 1.43
Tau protein is required for amyloid {beta}-induced impairment of hippocampal long-term potentiation. J Neurosci (2011) 1.43
Drug repositioning for Alzheimer's disease. Nat Rev Drug Discov (2012) 1.42
Increased 4R-Tau Induces Pathological Changes in a Human-Tau Mouse Model. Neuron (2016) 1.42
A high-affinity, dimeric inhibitor of PSD-95 bivalently interacts with PDZ1-2 and protects against ischemic brain damage. Proc Natl Acad Sci U S A (2012) 1.40
The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. Am J Pathol (2012) 1.36
Novel diffusion barrier for axonal retention of Tau in neurons and its failure in neurodegeneration. EMBO J (2011) 1.32
Amyloid-β oligomers induce synaptic damage via Tau-dependent microtubule severing by TTLL6 and spastin. EMBO J (2013) 1.31
The involvement of microRNAs in neurodegenerative diseases. Front Cell Neurosci (2013) 1.30
Antisense reduction of tau in adult mice protects against seizures. J Neurosci (2013) 1.29
Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer's disease. EMBO Mol Med (2012) 1.28
Initiation and propagation of neurodegeneration. Nat Med (2010) 1.25
Oligomeric Aβ-induced synaptic dysfunction in Alzheimer's disease. Mol Neurodegener (2014) 1.24
Recent progress in understanding Alzheimer's β-amyloid structures. Trends Biochem Sci (2011) 1.24
Frontotemporal dementia: implications for understanding Alzheimer disease. Cold Spring Harb Perspect Med (2012) 1.23
Cognitive defects are reversible in inducible mice expressing pro-aggregant full-length human Tau. Acta Neuropathol (2012) 1.21
Human P301L-mutant tau expression in mouse entorhinal-hippocampal network causes tau aggregation and presynaptic pathology but no cognitive deficits. PLoS One (2012) 1.19
Mouse models of Alzheimer's disease. Brain Res Bull (2011) 1.19
Animal models of Alzheimer disease. Cold Spring Harb Perspect Med (2012) 1.18
Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice. Nat Neurosci (2015) 1.18
A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric aβ, and frank neuronal loss. J Neurosci (2013) 1.17
Loss of fused in sarcoma (FUS) promotes pathological Tau splicing. EMBO Rep (2012) 1.17
Aging and amyloid beta-induced oxidative DNA damage and mitochondrial dysfunction in Alzheimer's disease: implications for early intervention and therapeutics. Biochim Biophys Acta (2011) 1.16
Protein phosphorylation in neurodegeneration: friend or foe? Front Mol Neurosci (2014) 1.15
Increased CDK5 expression in HIV encephalitis contributes to neurodegeneration via tau phosphorylation and is reversed with Roscovitine. Am J Pathol (2011) 1.15
Tau elevations in the brain extracellular space correlate with reduced amyloid-β levels and predict adverse clinical outcomes after severe traumatic brain injury. Brain (2011) 1.15
Tau in physiology and pathology. Nat Rev Neurosci (2015) 1.15
The dendritic hypothesis for Alzheimer's disease pathophysiology. Brain Res Bull (2013) 1.14
CREB-activity and nmnat2 transcription are down-regulated prior to neurodegeneration, while NMNAT2 over-expression is neuroprotective, in a mouse model of human tauopathy. Hum Mol Genet (2011) 1.12
Fyn inhibition rescues established memory and synapse loss in Alzheimer mice. Ann Neurol (2015) 1.11
Hsp90-Tau complex reveals molecular basis for specificity in chaperone action. Cell (2014) 1.11
Role of phosphatidylserine receptors in enveloped virus infection. J Virol (2014) 1.10
Antisense oligonucleotides: treating neurodegeneration at the level of RNA. Neurotherapeutics (2013) 1.10
Tau reduction does not prevent motor deficits in two mouse models of Parkinson's disease. PLoS One (2011) 1.10
Microtubule-associated protein tau is essential for long-term depression in the hippocampus. Philos Trans R Soc Lond B Biol Sci (2013) 1.10
A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of Aβ on synapses and dendritic spines. Hum Mol Genet (2011) 1.10
Longitudinal modeling of frontal cognition in APOE ε4 homozygotes, heterozygotes, and noncarriers. Neurology (2011) 1.09
GSK3 and Alzheimer's Disease: Facts and Fiction…. Front Mol Neurosci (2011) 1.09
Functional screening of Alzheimer pathology genome-wide association signals in Drosophila. Am J Hum Genet (2011) 1.08
Therapeutic strategies for tau mediated neurodegeneration. J Neurol Neurosurg Psychiatry (2012) 1.07
Tau exacerbates excitotoxic brain damage in an animal model of stroke. Nat Commun (2017) 1.07
Soluble aβ promotes wild-type tau pathology in vivo. J Neurosci (2012) 1.06
Age-appropriate cognition and subtle dopamine-independent motor deficits in aged tau knockout mice. Neurobiol Aging (2013) 1.06
Interaction between pathogenic proteins in neurodegenerative disorders. J Cell Mol Med (2012) 1.06
Spines, plasticity, and cognition in Alzheimer's model mice. Neural Plast (2011) 1.06
The importance of tau phosphorylation for neurodegenerative diseases. Front Neurol (2013) 1.05
Potential contribution of exosomes to the prion-like propagation of lesions in Alzheimer's disease. Front Physiol (2012) 1.05
The intersection of amyloid β and tau in glutamatergic synaptic dysfunction and collapse in Alzheimer's disease. Ageing Res Rev (2013) 1.05
Fyn-tau-amyloid: a toxic triad. Cell (2010) 1.05
Tau and tauopathies. Prog Mol Biol Transl Sci (2012) 1.04
Tau reduction prevents disease in a mouse model of Dravet syndrome. Ann Neurol (2014) 1.04
Abnormal tau, mitochondrial dysfunction, impaired axonal transport of mitochondria, and synaptic deprivation in Alzheimer's disease. Brain Res (2011) 1.04
Phosphorylation in the amino terminus of tau prevents inhibition of anterograde axonal transport. Neurobiol Aging (2011) 1.04
Formation and propagation of tau oligomeric seeds. Front Neurol (2013) 1.04
Origins of Alzheimer's disease: reconciling cerebrospinal fluid biomarker and neuropathology data regarding the temporal sequence of amyloid-beta and tau involvement. Curr Opin Neurol (2012) 1.04
Dendritic degeneration, neurovascular defects, and inflammation precede neuronal loss in a mouse model for tau-mediated neurodegeneration. Am J Pathol (2011) 1.04
Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol (2009) 7.50
Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science (2006) 6.47
Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science (2010) 3.98
Amyloid-β and tau--a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci (2010) 3.61
Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease. Science (2008) 3.59
Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat Neurosci (2004) 3.09
Formation and maintenance of Alzheimer's disease beta-amyloid plaques in the absence of microglia. Nat Neurosci (2009) 2.85
In vivo detection of amyloid-beta deposits by near-infrared imaging using an oxazine-derivative probe. Nat Biotechnol (2005) 2.81
Tropomyosin-based regulation of the actin cytoskeleton in time and space. Physiol Rev (2008) 2.73
Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression. Proc Natl Acad Sci U S A (2006) 2.66
Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci U S A (2013) 2.27
Induction of cerebral beta-amyloidosis: intracerebral versus systemic Abeta inoculation. Proc Natl Acad Sci U S A (2009) 2.27
Extracellular amyloid formation and associated pathology in neural grafts. Nat Neurosci (2003) 2.24
Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol (2012) 2.22
Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice. J Biol Chem (2005) 2.12
Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc Natl Acad Sci U S A (2009) 2.04
Invasion of hematopoietic cells into the brain of amyloid precursor protein transgenic mice. J Neurosci (2005) 1.94
Deletion of tumor necrosis factor death receptor inhibits amyloid beta generation and prevents learning and memory deficits in Alzheimer's mice. J Cell Biol (2007) 1.90
Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J Neurosci (2007) 1.85
Opioid agonists have different efficacy profiles for G protein activation, rapid desensitization, and endocytosis of mu-opioid receptors. J Biol Chem (2003) 1.78
Induction of tau pathology by intracerebral infusion of amyloid-beta -containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice. Am J Pathol (2007) 1.77
Reactive glia in the injured brain acquire stem cell properties in response to sonic hedgehog. [corrected]. Cell Stem Cell (2013) 1.77
The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease. J Biol Chem (2004) 1.75
Amyloid-associated neuron loss and gliogenesis in the neocortex of amyloid precursor protein transgenic mice. J Neurosci (2002) 1.72
Conus venom peptide pharmacology. Pharmacol Rev (2012) 1.69
Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Abeta protofibrils. Proc Natl Acad Sci U S A (2007) 1.68
Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models. J Exp Med (2008) 1.68
Brain estrogen deficiency accelerates Abeta plaque formation in an Alzheimer's disease animal model. Proc Natl Acad Sci U S A (2005) 1.67
Cognitive and physical activity differently modulate disease progression in the amyloid precursor protein (APP)-23 model of Alzheimer's disease. Biol Psychiatry (2006) 1.66
Soluble Aβ seeds are potent inducers of cerebral β-amyloid deposition. J Neurosci (2011) 1.66
Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia. Proc Natl Acad Sci U S A (2008) 1.64
Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice. J Biol Chem (2005) 1.64
Mu-opioid receptor desensitization: is morphine different? Br J Pharmacol (2004) 1.64
App gene dosage modulates endosomal abnormalities of Alzheimer's disease in a segmental trisomy 16 mouse model of down syndrome. J Neurosci (2003) 1.59
Dual induction of TREM2 and tolerance-related transcript, Tmem176b, in amyloid transgenic mice: implications for vaccine-based therapies for Alzheimer's disease. ASN Neuro (2010) 1.58
Tau promotes neurodegeneration via DRP1 mislocalization in vivo. Neuron (2012) 1.58
Critical role of soluble amyloid-β for early hippocampal hyperactivity in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2012) 1.58
Aging sensitizes toward ROS formation and lipid peroxidation in PS1M146L transgenic mice. Free Radic Biol Med (2005) 1.51
Pronuclear injection for the production of transgenic mice. Nat Protoc (2007) 1.50
Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J Neurosci (2006) 1.46
Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Abeta production in APP23 transgenic mice. Proc Natl Acad Sci U S A (2003) 1.46
Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLoS One (2011) 1.45
Soluble beta-amyloid leads to mitochondrial defects in amyloid precursor protein and tau transgenic mice. Neurodegener Dis (2008) 1.42
Cystatin C modulates cerebral beta-amyloidosis. Nat Genet (2007) 1.42
Altered morphology and 3D architecture of brain vasculature in a mouse model for Alzheimer's disease. Proc Natl Acad Sci U S A (2008) 1.42
Neuronal microRNA deregulation in response to Alzheimer's disease amyloid-beta. PLoS One (2010) 1.37
Neprilysin-sensitive synapse-associated amyloid-beta peptide oligomers impair neuronal plasticity and cognitive function. J Biol Chem (2006) 1.37
Molecular imaging of amyloid beta peptides in mouse brain sections using mass spectrometry. Anal Biochem (2002) 1.37
Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. Eur J Neurosci (2003) 1.36
Phosphorylation of actin-depolymerizing factor/cofilin by LIM-kinase mediates amyloid beta-induced degeneration: a potential mechanism of neuronal dystrophy in Alzheimer's disease. J Neurosci (2006) 1.35
Induction of delta-opioid receptor function in the midbrain after chronic morphine treatment. J Neurosci (2005) 1.35
Therapeutic approaches to Alzheimer's disease. Brain (2006) 1.34
Primary support cultures of hippocampal and substantia nigra neurons. Nat Protoc (2009) 1.33
Distinct cellular properties of identified dopaminergic and GABAergic neurons in the mouse ventral tegmental area. J Physiol (2011) 1.30
Imaging of peripheral benzodiazepine receptor expression as biomarkers of detrimental versus beneficial glial responses in mouse models of Alzheimer's and other CNS pathologies. J Neurosci (2008) 1.29
Capsaicin activation of glutamatergic synaptic transmission in the rat locus coeruleus in vitro. J Physiol (2002) 1.29
Amyloid beta-induced changes in nitric oxide production and mitochondrial activity lead to apoptosis. J Biol Chem (2004) 1.28
Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. Carcinogenesis (2013) 1.28
Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition. J Pharmacol Exp Ther (2008) 1.28
Mitochondrial dysfunction: the first domino in brain aging and Alzheimer's disease? Antioxid Redox Signal (2007) 1.28
Activation of the ERK and JNK signaling pathways caused by neuron-specific inhibition of PP2A in transgenic mice. Am J Pathol (2003) 1.24
Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models. Proc Natl Acad Sci U S A (2010) 1.24
Oligomeric and fibrillar species of beta-amyloid (A beta 42) both impair mitochondrial function in P301L tau transgenic mice. J Mol Med (Berl) (2008) 1.23
Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer's disease. PLoS One (2009) 1.23
Modulation of GABA release during morphine withdrawal in midbrain neurons in vitro. Neuropharmacology (2003) 1.22
Phosphorylated Tau interacts with c-Jun N-terminal kinase-interacting protein 1 (JIP1) in Alzheimer disease. J Biol Chem (2009) 1.21
Modeling familial Danish dementia in mice supports the concept of the amyloid hypothesis of Alzheimer's disease. Proc Natl Acad Sci U S A (2010) 1.21
Divergent phosphorylation pattern of tau in P301L tau transgenic mice. Eur J Neurosci (2008) 1.21
beta-Amyloid induces paired helical filament-like tau filaments in tissue culture. J Biol Chem (2003) 1.19
In vivo positron emission tomographic imaging of glial responses to amyloid-beta and tau pathologies in mouse models of Alzheimer's disease and related disorders. J Neurosci (2011) 1.19
Mechanistic involvement of the calpain-calpastatin system in Alzheimer neuropathology. FASEB J (2011) 1.18
APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques. Biochemistry (2002) 1.18
Amyloid-Beta interaction with mitochondria. Int J Alzheimers Dis (2011) 1.18
Mitochondrial dysfunction: common final pathway in brain aging and Alzheimer's disease--therapeutic aspects. Mol Neurobiol (2010) 1.17
Memory deficits in APP23/Abca1+/- mice correlate with the level of Aβ oligomers. ASN Neuro (2009) 1.17
Pathobiology of dynorphins in trauma and disease. Front Biosci (2005) 1.17
Opioid tolerance in periaqueductal gray neurons isolated from mice chronically treated with morphine. Br J Pharmacol (2005) 1.16
Convergence of amyloid-beta and tau pathologies on mitochondria in vivo. Mol Neurobiol (2010) 1.16
Age-dependent cerebrovascular abnormalities and blood flow disturbances in APP23 mice modeling Alzheimer's disease. J Neurosci (2003) 1.16
Age effects on the regulation of adult hippocampal neurogenesis by physical activity and environmental enrichment in the APP23 mouse model of Alzheimer disease. Hippocampus (2009) 1.15
Reference genes identified in SH-SY5Y cells using custom-made gene arrays with validation by quantitative polymerase chain reaction. Anal Biochem (2004) 1.15
GABA transporter currents activated by protein kinase A excite midbrain neurons during opioid withdrawal. Neuron (2005) 1.15
Reduced hippocampal MT2 melatonin receptor expression in Alzheimer's disease. J Pineal Res (2005) 1.14
Compromised hemodynamic response in amyloid precursor protein transgenic mice. J Neurosci (2002) 1.14
Expression of human beta-secretase in the mouse brain increases the steady-state level of beta-amyloid. J Neurochem (2002) 1.14